Basaloid squamous cell carcinoma of the maxillary sinus: Report of two cases in association with cathepsin K expression
- Authors:
- Published online on: April 17, 2013 https://doi.org/10.3892/ol.2013.1311
- Pages: 1755-1759
Abstract
Introduction
Basaloid squamous cell carcinoma (BSCC) is a rare variant of squamous cell carcinoma, which is characterized clinically by highly aggressive behavior and is histopathologically composed of basaloid and squamous components (1). BSCC was first reported by Wain et al in 1986 as a highly aggressive histopathological variant of squamous cell carcinoma occurring in the tongue, pharynx and larynx (2). Since this initial report, BSCC has been reported in various organs, including the esophagus, with the most common sites in the head and neck region being the oral cavity and larynx (1,3). The occurrence of BSCC in the nasal cavity is extremely rare and only 26 cases have been reported (3–9). In the present study, two additional cases of BSCC occurring in the maxillary sinus are reported and the clinicopathological features and immunohistochemical characteristics of this rare tumor are discussed. This study was approved by the ethics committee of Shiga University of Medical Science. Written informed consent was obtained from the patients.
Case reports
Case 1
An 85-year-old Japanese female patient presented with a nasal tumor and right-sided exophthalmos. Computed tomography (CT) and magnetic resonance imaging (MRI) scans revealed a right maxillary sinus tumor invading into the right ethmoid sinus, orbit and dura mater (Fig. 1). A biopsy specimen from the right maxillary sinus tumor indicated a diagnosis of BSCC (T4, N0, M0), and radiation therapy (58 Gy) with TS-1 administration was subsequently administered. CT and MRI scans following therapy showed that the tumor had contracted and a biopsy from the tumor showed a few residual degenerative carcinoma cells. The patient has survived with the disease for 10 months since the initial diagnosis.
Case 2
A 60-year-old Japanese male patient presented with an approximate three-month history of persistent nasal obstruction. CT revealed a right-sided maxillary sinus tumor with destruction of the surrounding bone tissues and dural invasion. A biopsy specimen from the maxillary sinus tumor revealed a poorly-differentiated carcinoma. Surgical resection of the maxillary sinus tumor was subsequently performed. Following surgery, the patient received chemotherapy. The post-operative course was uneventful, although local recurrence occurred one and a half years subsequent to the surgery. This was followed by the development of multiple liver and lung metastases to which the patient succumbed.
Materials and methods
The formalin-fixed, paraffin-embedded tissue blocks of the maxillary sinus specimens were cut into 3-μm thick sections, then deparaffinized and rehydrated. Each section was stained with hematoxylin and eosin, then used for immunostaining. Immunohistochemical analyses were performed using an autostainer (Benchmark XT system, Ventana Medical Systems, Tucson, AZ, USA) according to the manufacturer’s instructions. The following primary antibodies were used: mouse monoclonal antibody against α-smooth muscle actin (alphasm-1; Novocastra Laboratories, Ltd., Newcastle upon Tyne, UK), mouse monoclonal antibody against cathepsin K (3F9; Abcam, Cambridge, UK), mouse monoclonal antibody against cytokeratin (AE1/AE3; DAKO Cytomation, Glostrup, Denmark), mouse monoclonal antibody against high molecular weight cytokeratin (34betaE12; DAKO Cytomation), mouse monoclonal antibody against epithelial membrane antigen (GP1.4; Novocastra), mouse monoclonal antibody against p63 (7JUL; Novocastra) and mouse monoclonal antibody against vimentin (VIM3B4; Novocastra).
Histopathological results
Case 1
The biopsy specimen from the maxillary sinus tumor exhibited an infiltrative proliferation of solid epithelial nests composed of basaloid cells and the surface epithelium was eroded (Fig. 2A). These basaloid cells had a high nuclear/cytoplasmic ratio, hyperchromatic nuclei without conspicuous nucleoli and scant cytoplasm (Figs. 2A and B). Mitotic figures were scattered and apoptotic bodies were frequently observed (Fig. 2B). The characteristic histopathological finding was the presence of spherical hyalinized materials within the tumor nests (Fig. 2A, arrows). No keratinization was observed in the tumor cells.
Case 2
The surgically resected specimen of the maxillary sinus showed an infiltrative proliferation of solid epithelial nests composed of the basaloid cells that had scant cytoplasm and hyperchromatic nuclei without conspicuous nucleoli (Fig. 3). Spherical hyalinized materials were present within the tumor nests (Fig. 3, arrows) and mitotic figures were scattered. Focal squamous differentiation, including individual keratinization and intercellular bridging, was also observed.
Immunohistochemical results
Table I shows the immunohistochemical findings of cases 1 and 2, each revealing similar results. The characteristic findings were diffuse positive immunoreactivity for p63 (Fig. 4A), negative immunoreactivity for α-smooth muscle actin and perinuclear dot-like positivity for vimentin (Fig. 4B). In addition, cathepsin K was diffusely expressed in each of the two cases (Fig. 4C).
Discussion
In the present study, two cases of BSCC of the maxillary sinus are described. The clinicopathological features of the 26 previously reported cases of BSCC of the nasal cavity, as well as the 2 present cases, are shown in Table II. BSCC mainly affects the elderly (particularly individuals between 60 and 80 years of age), although it may occur, albeit rarely, in young adults. A comparison of all 28 cases showed that males are more commonly affected (male/female 18:10) and that the most common clinical symptoms are nasal obstruction, epistaxis and nasal tumors. The prognosis of BSCC of the nasal cavity is poor; 14 of the 28 reported cases succumbed to the disease and only seven were free of tumors following treatment. BSCC of the head and neck region shows aggressive clinical behavior [frequent lymph node metastases (62.5%), high mortality rate (47.5%) and poor three- and five-year overall survival rates (50% and 38.5%, respectively)] (10). Additionally, the present survey of the clinicopathological features of BSCC of the nasal cavity in all reported cases revealed that it has an aggressive clinical course, which corresponds to that of BSCC of the other head and neck regions.
The main histopathological differential diagnostic consideration for BSCC is adenoid cystic carcinoma (particularly the solid variant) since these tumors are also composed of basaloid cells and may have areas with a cribriform growth pattern (11). The main histopathological characteristics of BSCC that aid in distinguishing it from adenoid cystic carcinoma are greater nuclear pleomorphism, evidence of squamous differentiation, presence of necrosis and abundant mitotic figures (11). Moreover, immunohistochemical analyses are also useful for differentiating between these two diseases. The majority of adenoid cystic carcinomas show positive immunoreactivity for smooth muscle actin, but this marker is negative in BSCC (11). Moreover, p63 is diffusely expressed in the basaloid cells of BSCC, while this protein is only observed in the peripheral cells of adenoid cystic carcinoma (12). In addition, perinuclear dot-like vimentin expression is characteristic of BSCC, in contrast to the diffuse cytoplasmic expression of adenoid cystic carcinoma (11). In the present two cases, the histopathological features, including nuclear pleomorphism, evidence of squamous differentiation and frequent mitotic figures, and the immunohistochemical characteristics (diffuse p63 positivity, perinuclear dot-like vimentin expression and smooth muscle actin negativity) led to the final diagnosis of BSCC of the maxillary sinus.
To further identify the markers of this devastating disease, the expression of cathepsin K, a cysteine protease with marked collagenolytic and elastolytic activities, was investigated. Cathepsin K cleaves multiple sites within the triple helix of collagen types I and III, as well as at extracellular regions, whereas other proteases are more limited in their proteolytic activities. Cathepsin K was first demonstrated to play a significant role in osteoclast-mediated bone resorption (13), and it has also been recognized that this protein is involved in the extracellular matrix turnover in certain organs (13). Previous studies have demonstrated a role for cathepsin K in malignant tumors in certain organs, including the breast, skin and lungs (14–18). The majority of malignant melanoma cases (10/12) showed marked cathepsin K expression in the tumor cells (15), while all 50 cases of cutaneous basal cell carcinoma also showed expression of this protease (16). These results suggest that cathepsin K expression in tumor cells contributes to tumor invasion (15,16). By contrast, the majority of squamous cell carcinomas of the skin exhibited no positive immunoreactivity for cathepsin K in the tumor cells (only 2/38 cases were weakly positive), while the peritumoral stromal cells were markedly positive for cathepsin K (19). Moreover, cathepsin K expression was noted in only 31% of the cases of esophageal invasive squamous cell carcinoma (being particularly confined to the relatively sparse cancer cells located externally in the tumor foci) (20). Diffuse cathepsin K expression was observed in the two present BSCC cases. Therefore, although only two cases were examined in the present study, diffuse cathepsin K expression may be a characteristic immunohistochemical feature of BSCC. Moreover, cathepsin K expression in BSCC may contribute to tumor invasion and its highly aggressive clinical course since this protein has marked collagenolytic and elastolytic activities. Additional clinicopathological analyses are consequently required to clarify these issues and potentially aid in the future treatment of BSCC.
References
Cardesa A, Zidar N and Ereño C: Basaloid squamous cell carcinoma. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Barnes L, Eveson JW, Reichart P and Sidransky D: IARC Press; Lyon: pp. 124–125. 2005 | |
Wain SL, Kier R, Vollmer RT and Bossen EH: Basaloid-squamous cell carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. Hum Pathol. 17:1158–1166. 1986. View Article : Google Scholar : PubMed/NCBI | |
Oikawa K, Tabuchi K, Nomura M, et al: Basaloid squamous cell carcinoma of the maxillary sinus: a report of two cases. Auris Nasus Larynx. 34:119–123. 2007. View Article : Google Scholar : PubMed/NCBI | |
Paulino AF, Singh B, Shah JP and Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope. 110:1479–1482. 2000. View Article : Google Scholar : PubMed/NCBI | |
Wan SK, Chan JK and Tse KC: Basaloid-squamous carcinoma of the nasal cavity. J Laryngol Otol. 106:370–371. 1992. View Article : Google Scholar : PubMed/NCBI | |
Wieneke JA, Thompson LDR and Wenig BM: Basaloid squamous cell carcinoma of the sinonasal tract. Cancer. 85:841–854. 1999. View Article : Google Scholar : PubMed/NCBI | |
Lu SY, Eng HL, Huang CC, Chien CY, Lui CC and Lin JW: Basaloid squamous cell carcinoma of the sinonasal tract: report of two cases. Otolaryngol Head Neck Surg. 134:883–885. 2006. View Article : Google Scholar : PubMed/NCBI | |
Yu GY, Gao Y, Peng X, Chen Y, Zhao FY and Wu MJ: A clinicopathologic study on basaloid squamous cell carcinoma in the oral and maxillofacial region. Int J Oral Maxillofac Surg. 37:1003–1008. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lee JS, Ko IJ, Jun SY and Kim JY: Basaloid squamous cell carcinoma in nasal cavity. Clin Exp Otorhinolaryngol. 2:207–210. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ereño C, Gaafar A, Garmendia M, Etxezarraga C, Bilbao FJ and López JI: Basaloid squamous cell carcinoma of the head and neck: a clinicopathological and follow-up study of 40 cases and review of the literature. Head and Neck Pathol. 2:83–91. 2008.PubMed/NCBI | |
Barnes L, Ferlito A, Altavilla G, MacMillan C, Rinaldo A and Doglioni C: Basaloid squamous cell carcinoma of the head and neck: clinicopathological features and differential diagnosis. Ann Otol Rhinol Laryngol. 105:75–82. 1996. View Article : Google Scholar : PubMed/NCBI | |
Emanuel P, Wang B, Wu M and Burstein DE: p63 immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol. 18:645–650. 2005. View Article : Google Scholar : PubMed/NCBI | |
Garnero P, Borel O, Byrjalsen I, et al: The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 273:32347–32352. 1998. View Article : Google Scholar : PubMed/NCBI | |
Mohamed MM and Sloane BF: Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 6:764–775. 2006. View Article : Google Scholar : PubMed/NCBI | |
Quintanilla-Dieck MJ, Codriansky K, Keady M, et al: Cathepsin K in melanoma invasion. J Invest Dermatol. 128:2281–2288. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ishida M, Kojima F and Okabe H: Cathepsin K expression in basal cell carcinoma. Eur Acad Dermatol Venereol. 27:e128–e130. 2013. View Article : Google Scholar : PubMed/NCBI | |
Littlewood-Evans AJ, Bilbe G, Bowler WB, et al: The osteoclast-associated protease cathepsin K is expressed in human breast cancer. Cancer Res. 57:5386–5390. 1997.PubMed/NCBI | |
Rapa I, Volante M, Cappia S, et al: Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. Am J Clin Pathol. 125:847–854. 2006. View Article : Google Scholar : PubMed/NCBI | |
Yan X, Takahara M, Xie L, et al: Stromal expression of cathepsin K in squamous cell carcinoma. Eur Acad Dermatol Venereol. 25:362–365. 2011. View Article : Google Scholar : PubMed/NCBI | |
Szumilo J, Burdan F, Zinkiewicz K, et al: Expression of syndecan-1 and cathepsin D and K in advanced esophageal squamous cell carcinoma. Folia Histochem Cytobiol. 47:571–578. 2009.PubMed/NCBI |